ArticleScientific reports2026
4-Hydroxycinnamic acid and Itaconic acid exhibit broad spectrum synergy with conventional antibiotics in inhibiting multidrug-resistant Salmonella Typhimurium.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Antimicrobial and Antibiofilm Activity Optimization of aMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
One approach to combating the surge in bacterial antimicrobial resistance is to use adjuvants that sensitize drug-resistant strains to conventional antibiotics. Here, we evaluated 24 pure bioactive compounds for their antibiotic adjuvant activity against a multidrug-resistant strain of Salmonella Typhimurium (DT104). All 24 bioactive compounds exhibited measurable antibacterial activity against DT104, with MIC values ranging from 0.036 to 4 mg/mL. Moreover, four bioactive compounds, namely p-coumaric acid, 4-hydroxycinnamic acid, itaconic acid, and cinnamic acid, sensitized DT104 to five antibiotics: ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline. Bioactive compounds, specifically 4-hydroxycinnamic acid and itaconic acid, induced the largest reductions in antibiotic MICs (1024- and 256-fold, respectively). Besides, 4-hydroxycinnamic acid was also synergistic with ciprofloxacin and inhibited the growth of ciprofloxacin-resistant strains of foodborne Salmonella (16-fold). The broad antibiotic adjuvant efficiency of 4-hydroxycinnamic acid was also demonstrated against multidrug-resistant strains of Escherichia coli and Klebsiella pneumoniae. Subsequent checkerboard analysis revealed that bioactive compounds maintained their antibiotic adjuvant activity even at their 0.5 × MIC levels. Subsequent time-kill kinetic studies confirmed the results of the checkerboard analysis. Overall, we demonstrate that 4-hydroxycinnamic and itaconic acid can sensitize drug-resistant bacteria to multiple antibiotics and can function as highly effective antibiotic adjuvants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.